What Is MOAT? VanEck Morningstar Wide Moat ETF

The first screen is qualitative. Morningstar's equity analysts assign moat ratings based on durable competitive advantages such as switching costs, network effects, cost advantage, intangible assets and efficient scale. Only the wide-moat group, companies judged able to defend excess returns for a long period, is eligible. That judgement comes from human analysts, not from a formula, which is unusual for an index-tracking product.

The second screen is valuation. From the eligible set, the index takes those trading furthest below Morningstar's own fair value estimates and weights them roughly equally. This is why the top of the fund is so flat, and why the names there are frequently unloved: Masco at 2.9%, Kenvue at 2.6%, Bristol-Myers Squibb at 2.5% and Zimmer Biomet at 2.4% are not the companies that lead a momentum-driven market.

The consequence people underestimate is turnover. When a holding rallies toward fair value, it is sold and replaced with something cheaper, on a staggered rebalancing schedule. MOAT is systematically selling what has worked and buying what has not, within a quality-constrained universe.

Two things break the resemblance. Weighting is near-equal rather than by market capitalisation, so a $30B company and a $300B company can carry the same 2.5%. And the valuation screen actively excludes expensive companies, which in recent years has meant excluding several of the largest US technology businesses at exactly the times they were driving the index.

The stated sector mix is technology 31%, consumer staples 18% and healthcare 18%, with consumer discretionary at 11% and industrials at 10%. That staples and healthcare weight, at 36% combined, is far above the broad market and is the more informative number. Brown-Forman, Kenvue, Mondelez, Bristol-Myers Squibb, Danaher and Zimmer Biomet are all top-ten positions.

Anyone buying MOAT expecting a large-blend fund that behaves like the market will be repeatedly surprised, in both directions. Divergence is the mechanism working, not a tracking failure.

At 0.46%, MOAT costs several times what a broad US index fund does and roughly double a typical factor fund. The fee pays for the analyst research underlying the moat ratings and the fair value estimates, which cannot be automated from public filings. Whether that is worth paying depends entirely on whether those estimates add something, and there is no way to verify that from the fee schedule.

The dependency is worth stating plainly: the portfolio is a direct expression of one research house's opinions about competitive advantage and intrinsic value. If those opinions are systematically wrong about a sector or a period, the fund inherits that error. This is closer to outsourced active management wrapped in an index than to a rules-based factor product.

It is a poor fit as a sole US holding, given the concentration into 40 or so names and the sector skew. It fits more naturally as a quality-and-valuation sleeve beside a cap-weighted core, where its divergence is the reason for holding it rather than a problem to explain.

Approximate weights as of August 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get MOAT exposure. Buy shares (or fractional shares) of MOAT directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so MOAT sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. MOAT trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether MOAT is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks the Morningstar Wide Moat Focus Index, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is MOAT a buy?

MOAT gives you the Morningstar Wide Moat Focus Index exposure in one ticker at a 0.46% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether MOAT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is MOAT a buy?

MOAT yields 1.35% as of August 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see MOAT dividend: yield and schedule.

New to funds like MOAT? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.